AIMS: Atypical (World Health Organization grade II) meningiomas have moderately high recurrence rates; even for completely resected tumours, approximately one-third will recur. Post-operative radiotherapy may aid local control and improve survival, but carries the risk of side effects. More accurate prediction of recurrence risk is therefore needed for patients with atypical meningioma. Previously, we used high-resolution array comparative genomic hybridization to identify genetic variations in 47 primary atypical meningiomas and found that approximately 60% of tumours show gain of 1q at 1q25.1 and 1q25.3 to 1q32.1 and that 1q gain appeared to correlate with shorter progression-free survival. This study aimed to validate and extend these findings in an independent sample. METHODS: Eighty-six completely resected atypical meningiomas (with 25 recurrences) from two neurosurgical centres in Ireland were identified and clinical follow-up was obtained. Utilizing a dual-colour interphase fluorescence in situ hybridization assay, 1q gain was assessed using Bacterial Artificial Chromosome probes directed against 1q25.1 and 1q32.1. RESULTS: The results confirm the high prevalence of 1q gain at these loci in atypical meningiomas. We further show that gain at 1q32.1 and age each correlate with progression-free survival in patients who have undergone complete surgical resection of atypical meningiomas. CONCLUSIONS: These independent findings suggest that assessment of 1q copy number status can add clinically useful information for the management of patients with atypical meningiomas.
AIMS: Atypical (World Health Organization grade II) meningiomas have moderately high recurrence rates; even for completely resected tumours, approximately one-third will recur. Post-operative radiotherapy may aid local control and improve survival, but carries the risk of side effects. More accurate prediction of recurrence risk is therefore needed for patients with atypical meningioma. Previously, we used high-resolution array comparative genomic hybridization to identify genetic variations in 47 primary atypical meningiomas and found that approximately 60% of tumours show gain of 1q at 1q25.1 and 1q25.3 to 1q32.1 and that 1q gain appeared to correlate with shorter progression-free survival. This study aimed to validate and extend these findings in an independent sample. METHODS: Eighty-six completely resected atypical meningiomas (with 25 recurrences) from two neurosurgical centres in Ireland were identified and clinical follow-up was obtained. Utilizing a dual-colour interphase fluorescence in situ hybridization assay, 1q gain was assessed using Bacterial Artificial Chromosome probes directed against 1q25.1 and 1q32.1. RESULTS: The results confirm the high prevalence of 1q gain at these loci in atypical meningiomas. We further show that gain at 1q32.1 and age each correlate with progression-free survival in patients who have undergone complete surgical resection of atypical meningiomas. CONCLUSIONS: These independent findings suggest that assessment of 1q copy number status can add clinically useful information for the management of patients with atypical meningiomas.
Authors: S Hing; Y J Lu; B Summersgill; L King-Underwood; J Nicholson; P Grundy; R Grundy; M Gessler; J Shipley; K Pritchard-Jones Journal: Am J Pathol Date: 2001-02 Impact factor: 4.307
Authors: R G Weber; J Boström; M Wolter; M Baudis; V P Collins; G Reifenberger; P Lichter Journal: Proc Natl Acad Sci U S A Date: 1997-12-23 Impact factor: 11.205
Authors: John Y K Lee; Sydney Finkelstein; Ronald L Hamilton; Rapaka Rekha; Joseph T King; Bennett Omalu Journal: Neurosurgery Date: 2004-11 Impact factor: 4.654
Authors: Frank Mendrzyk; Andrey Korshunov; Axel Benner; Grischa Toedt; Stefan Pfister; Bernhard Radlwimmer; Peter Lichter Journal: Clin Cancer Res Date: 2006-04-01 Impact factor: 12.531
Authors: Angel Maillo; Alberto Orfao; José María Sayagues; Pedro Diaz; Juan Antonio Gómez-Moreta; Marcelino Caballero; David Santamarta; Angel Santos-Briz; Francisco Morales; María Dolores Tabernero Journal: J Clin Oncol Date: 2003-09-01 Impact factor: 44.544
Authors: C M Hattinger; U Pötschger; M Tarkkanen; J Squire; M Zielenska; S Kiuru-Kuhlefelt; L Kager; P Thorner; S Knuutila; F K Niggli; P F Ambros; H Gadner; D R Betts Journal: Br J Cancer Date: 2002-06-05 Impact factor: 7.640
Authors: Cheng-Ying Ho; Stacy Mosier; Janice Safneck; Diva R Salomao; Neil R Miller; Charles G Eberhart; Christopher D Gocke; Denise A S Batista; Fausto J Rodriguez Journal: Brain Pathol Date: 2014-05-21 Impact factor: 6.508
Authors: Nicole M A White; Daniel W Newsted; Olena Masui; Alexander D Romaschin; K W Michael Siu; George M Yousef Journal: Tumour Biol Date: 2013-10-19
Authors: Sharon K Michelhaugh; Anthony R Guastella; Kaushik Varadarajan; Neil V Klinger; Prahlad Parajuli; Aamir Ahmad; Seema Sethi; Amro Aboukameel; Sam Kiousis; Ian M Zitron; Salah A Ebrahim; Lisa A Polin; Fazlul H Sarkar; Aliccia Bollig-Fischer; Sandeep Mittal Journal: J Transl Med Date: 2015-07-15 Impact factor: 5.531
Authors: Patrícia Domingues; María González-Tablas; Álvaro Otero; Daniel Pascual; Laura Ruiz; David Miranda; Pablo Sousa; Jesús María Gonçalves; María Celeste Lopes; Alberto Orfao; María Dolores Tabernero Journal: Oncotarget Date: 2015-05-10